We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 3

1.
FIG. 1.

FIG. 1. From: Two Studies Evaluating the Safety and Immunogenicity of a Live, Attenuated Shigella flexneri 2a Vaccine (SC602) and Excretion of Vaccine Organisms in North American Volunteers .

Time course of adverse events in 34 subjects of the outpatient trial. The bars represent the total number of volunteers reporting symptoms per day.

David E. Katz, et al. Infect Immun. 2004 February;72(2):923-930.
2.
FIG. 2.

FIG. 2. From: Two Studies Evaluating the Safety and Immunogenicity of a Live, Attenuated Shigella flexneri 2a Vaccine (SC602) and Excretion of Vaccine Organisms in North American Volunteers .

Fold increase in serum IgA, IgG, and IgM antibody titers to S. flexneri 2a lipopolysaccharide. (A) Outpatient study. (B) Inpatient study. The dashed line identifies the threshold of response. The solid lines define the median increase (n = fold).

David E. Katz, et al. Infect Immun. 2004 February;72(2):923-930.
3.

FIG. 3. From: Two Studies Evaluating the Safety and Immunogenicity of a Live, Attenuated Shigella flexneri 2a Vaccine (SC602) and Excretion of Vaccine Organisms in North American Volunteers .

Excretion of SC602 by volunteers. Symbols represent culture-positive stools (X) and culture-negative stools (−). No entry for a collection day indicates that no sample was collected. The shaded area represents the duration of colonization. (A) Outpatient study: volunteers received antibiotics from days 35 to 39. (B) Inpatient study: volunteers received antibiotics from days 8 to 12.

David E. Katz, et al. Infect Immun. 2004 February;72(2):923-930.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk